EGFR and lung adenocarcinoma: Especially in lung adenocarcinoma, great improvement is taking place in targeted therapies, nearly ten genes have been developed as drug targets, including epidermal growth factor receptor (EGFR), anaplasticlymphoma kinase (ALK), ROS1, RET, HER2, BRAF, PIK3CA, Kras, Nras and MET [6–8] the drugs that are developed based on these genes expression situation are all showing exciting curative effect [8–14].